RecruitingNCT06275373

The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid Dysfunction

Sponsor

Walter Reed National Military Medical Center

Enrollment

100 participants

Start Date

May 12, 2021

Study Type

OBSERVATIONAL

Conditions

Graves Disease Thyroid Eye Disease Graves Ophthalmopathy

Summary

This protocol studies the clinical outcome of patients with active thyroid disease with visually significant signs and symptoms of proptosis, pain, diplopiam lid/orbital edema, or lid/orbital erythema recommended for treatment with teprotumumab infusion (Tepezza®). Patients recommended for treatment will be evaluated by an oculoplastic surgeon (Dr. Eva Chou) and endocrinologist (Dr. Thanh Hoang).

Eligibility

Min Age: 18 Years

Inclusion Criteria3

only DOD beneficiaries
adult patients 18 years of age or older
adult patients with proptosis, ocular/orbital pain, diplopia, lid/orbital edema, or lid/orbital erythema associated with autoimmune thyroid disease

Exclusion Criteria5

Patients with evidence of compressive optic neuropathy necessitating urgent orbital decompression or external beam radiation
patients with a history of uncontrolled diabetes mellitus
patients with a history/diagnosis of uncontrolled inflammatory bowel disease
patients under age 18 years
patients who are pregnant or trying to become pregnant.

Print for Your Doctor

Interested in this trial?

Get notified about updates and connect with the research team.